Motus GI Holdings, Inc. (MOTS)
OTCMKTS: MOTS · Delayed Price · USD
0.0810
+0.0010 (1.25%)
Apr 26, 2024, 3:29 PM EDT - Market closed
Motus GI Holdings Revenue
In the year 2023, Motus GI Holdings had annual revenue of $319.00K, a decrease of -46.11%. Revenue in the quarter ending December 31, 2023 was $64.00K, a -41.28% decrease year-over-year.
Revenue (ttm)
$319.00K
Revenue Growth
-46.11%
P/S Ratio
1.32
Revenue / Employee
$21,267
Employees
15
Market Cap
422.08K USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 319.00K | -273.00K | -46.11% |
Dec 31, 2022 | 592.00K | 201.00K | 51.41% |
Dec 31, 2021 | 391.00K | 293.00K | 298.98% |
Dec 31, 2020 | 98.00K | -9.00K | -8.41% |
Dec 31, 2019 | 107.00K | 71.00K | 197.22% |
Dec 31, 2018 | 36.00K | 29.00K | 414.29% |
Dec 31, 2017 | 7.00K | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
MOTS News
- 5 weeks ago - Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer - Business Wire
- 2 months ago - Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds - GlobeNewsWire
- 2 months ago - Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract - GlobeNewsWire
- 2 months ago - Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders - GlobeNewsWire
- 3 months ago - Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation - GlobeNewsWire
- 4 months ago - Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA) - Benzinga
- 4 months ago - Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering - GlobeNewsWire